Department of Neurosurgery, Mayo Clinic, Jacksonville, FL.
Department of Neurosurgery, Mayo Clinic, Jacksonville, FL.
Mayo Clin Proc. 2024 Feb;99(2):229-240. doi: 10.1016/j.mayocp.2023.10.016.
To establish a neurologic disorder-driven biospecimen repository to bridge the operating room with the basic science laboratory and to generate a feedback cycle of increased institutional and national collaborations, federal funding, and human clinical trials.
Patients were prospectively enrolled from April 2017 to July 2022. Tissue, blood, cerebrospinal fluid, bone marrow aspirate, and adipose tissue were collected whenever surgically safe. Detailed clinical, imaging, and surgical information was collected. Neoplastic and nonneoplastic samples were categorized and diagnosed in accordance with current World Health Organization classifications and current standard practices for surgical pathology at the time of surgery.
A total of 11,700 different specimens from 813 unique patients have been collected, with 14.2% and 8.5% of patients representing ethnic and racial minorities, respectively. These include samples from a total of 463 unique patients with a primary central nervous system tumor, 88 with metastasis to the central nervous system, and 262 with nonneoplastic diagnoses. Cerebrospinal fluid and adipose tissue dedicated banks with samples from 130 and 16 unique patients, respectively, have also been established. Translational efforts have led to 42 new active basic research projects; 4 completed and 6 active National Institutes of Health-funded projects; and 2 investigational new drug and 5 potential Food and Drug Administration-approved phase 0/1 human clinical trials, including 2 investigator initiated and 3 industry sponsored.
We established a comprehensive biobank with detailed notation with broad potential that has helped us to transform our practice of research and patient care and allowed us to grow in research and clinical trials in addition to providing a source of tissue for new discoveries.
建立一个以神经障碍为导向的生物标本库,将手术室与基础科学实验室联系起来,并形成一个增加机构和国家合作、联邦资金和人类临床试验的反馈循环。
从 2017 年 4 月至 2022 年 7 月,前瞻性招募患者。只要手术安全,就收集组织、血液、脑脊液、骨髓抽吸物和脂肪组织。收集详细的临床、影像学和手术信息。按照当前的世界卫生组织分类和手术时的外科病理学现行标准,对肿瘤和非肿瘤样本进行分类和诊断。
共收集了 813 名患者的 11700 种不同标本,其中 14.2%和 8.5%的患者分别代表少数民族和少数族裔。其中包括 463 名原发性中枢神经系统肿瘤患者、88 名中枢神经系统转移患者和 262 名非肿瘤性诊断患者的样本。还建立了专门用于收集 130 名和 16 名独特患者脑脊液和脂肪组织的银行。转化努力导致 42 个新的活跃基础研究项目;4 个已完成和 6 个正在进行的美国国立卫生研究院资助项目;以及 2 个研究性新药和 5 个潜在的食品和药物管理局批准的 0/1 期人体临床试验,包括 2 个由研究者发起和 3 个由行业赞助。
我们建立了一个具有广泛潜力的全面生物库,具有详细的注释,这帮助我们改变了我们的研究和患者护理实践,并使我们能够在研究和临床试验中发展,除了为新发现提供组织来源。